Medicare will likely choose the obesity drug semaglutide for price negotiation 'within the next few years,' according to a new analysis from nonpartisan congressional budget experts.
A San Diego biotech is working on therapies that could tackle life-altering conditions, like autoimmune diseases and cancer, by modifying cells. But instead of engineering cells in a lab, they’re doing it inside your body
Eli Lilly's powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk's rival obesity medicine Wegovy for the first time since it was launched.
A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson of providing drug pricing tools to doctors for free, to induce them to buy drugs from the company.